文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

抗VEGF时代的早产儿视网膜病变:筛查体系与治疗决策

Retinopathy of prematurity in the anti-VEGF era: Screening systems and practical treatment decision-making across anti-VEGF, laser, and surgery.
PubMed 文献 · Prog Retin Eye Res · 2026-09-23

本文综述抗VEGF时代早产儿视网膜病变(ROP)的全程管理,涵盖分类、筛查、治疗决策、手术及长期结局。抗VEGF可快速消退后部及侵袭性ROP并允许周边血管继续发育,但带来持续无血管视网膜、延迟复发、再治疗不确定及全身安全性问题。治疗成功应超越短期消退,延伸至血管化持续、牵引并发症预防和发育随访。

要点

  • 抗VEGF最适合I区、后部II区及侵袭性ROP,激光仍用于前部病变、随访不可靠及残留无血管视网膜。
  • 雷珠单抗和阿非西普全身安全性似优于贝伐珠单抗,但长期对比数据有限。
  • 抗VEGF后需警惕持续无血管视网膜、延迟复发和再治疗不确定性。

核心结论

  • 抗VEGF时代ROP治疗成功应扩展至持续视网膜血管化、牵引并发症预防和持续发育随访。

研究设计与样本

  • 本文为综述,汇总ROP照护路径中分类、筛查、治疗决策、手术及长期结局的证据。

主要发现

  • 抗VEGF可快速消退后部及侵袭性ROP,并可能允许周边血管继续发育。
  • 抗VEGF带来持续无血管视网膜、延迟复发、再治疗不确定及全身安全性挑战。
  • 雷珠单抗和阿非西普全身安全性似优于贝伐珠单抗,但长期对比数据有限。
  • 法瑞西单抗和局部地塞米松仍处于研究阶段。

关键数值与推荐

  • 抗VEGF治疗最受支持用于I区、后部II区及侵袭性ROP。
  • 激光仍重要用于前部病变、随访不可靠环境及残留无血管视网膜。
  • 晚期牵引性病变仍需手术。

临床怎么用

  • 根据病变分区和侵袭性选择抗VEGF或激光,前部病变及随访不可靠时优先激光。
  • 抗VEGF后需长期随访监测持续无血管视网膜、延迟复发和再治疗需求。
  • 关注抗VEGF全身安全性,雷珠单抗和阿非西普可能更优但需更多数据。

局限性

  • 抗VEGF长期对比数据仍有限。
  • 法瑞西单抗和局部地塞米松仍处于研究阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Retinopathy of prematurity (ROP) is a vasoproliferative disease of the incompletely vascularized retina and remains a major preventable cause of childhood blindness. Its clinical profile varies by region: in high-income countries, severe ROP mainly affects extremely preterm infants, whereas in many low- and middle-income countries (LMICs), it may also occur in larger, more mature infants because neonatal survival has improved faster than screening capacity. The introduction of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has changed ROP management. Anti-VEGF agents can rapidly regress posterior and aggressive ROP (A-ROP) and may allow continued peripheral vascularization, but they also introduce challenges including persistent avascular retina (PAR), delayed reactivation, retreatment uncertainty, and systemic safety concerns. This review summarizes evidence across the ROP care pathway, including classification, screening, treatment decision-making, surgery, and long-term outcomes. In the anti-VEGF era, treatment success should extend beyond short-term regression to continued retinal vascularization, prevention of tractional complications, and sustained developmental follow-up. Anti-VEGF therapy is best supported for Zone I, posterior Zone II, and A-ROP, whereas laser remains important for anterior disease, unreliable follow-up settings, and residual avascular retina. Surgery remains necessary for advanced tractional disease. Ranibizumab and aflibercept appear to have more reassuring systemic profiles than bevacizumab, although long-term comparative data remain limited. Faricimab and topical dexamethasone remain investigational. Future priorities include integrated screening networks, standardized retreatment algorithms, and longitudinal registries tracking ocular and developmental outcomes.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Zhang X, Zhang W, Yang Y, et al. Retinopathy of prematurity in the anti-VEGF era: Screening systems and practical treatment decision-making across anti-VEGF, laser, and surgery. Prog Retin Eye Res. 2026. PMID: 42777939. doi:10.1016/j.preteyeres.2026.101531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。